Skip to main content
INCY
NASDAQ Life Sciences

Povofortay Wins EU Approval as First Once-Daily Oral HS Treatment

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$117.533
Mkt Cap
$24.515B
52W Low
$89.25
52W High
$132.6
52W Position info
32% above low
Off High info
11% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

INCY sits 32% above its 52-week low of $89.25.

Summary

The European Commission approved Povofortay (povorcitinib) 45 mg and 75 mg for adults with moderate to severe hidradenitis suppurativa who have failed or cannot take anti-TNF therapy. It is the first once-daily oral treatment cleared in the EU for this disease, based on the Phase 3 STOP-HS1 and STOP-HS2 trials, where up to 71.4% of patients hit HiSCR50 through Week 54. CEO Bill Meury called it a key growth driver, and the approval gives Incyte a new commercial asset in Europe beyond its Jakafi-dependent hematology base. The bigger prize is still pending: the FDA is reviewing the same NDA, with U.S. approval and launch anticipated in the first quarter of 2027. This lands after the October 29 guidance raise to $5.21-$5.30 billion and the November 13 decision to drop the Phase 3 MAESTRA-3 ovarian cancer study, so it reinforces the inflammation and autoimmunity franchise as the growth story.

At the time of this announcement, INCY was trading at $117.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.5B. The 52-week trading range was $89.25 to $132.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

INCY - Latest Insights

INCY
Oct 29, 2026, 4:03 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $116.80
Real-time Price: $116.74 info
Change: -$0.0567 (-0.05%) info
Market Cap: $24.515B info
INCY
Oct 29, 2026, 11:07 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $115.20
Real-time Price: $116.74 info
Change: +$1.54 (+1%) info
Market Cap: $24.515B info
INCY
Oct 29, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $117.76
Real-time Price: $116.74 info
Change: -$1.02 (-0.86%) info
Market Cap: $24.515B info
INCY
Aug 31, 2026, 4:34 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $123.22
Real-time Price: $116.74 info
Change: -$6.48 (-5%) info
Market Cap: $24.515B info
INCY
Jul 29, 2026, 6:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $119.00
Real-time Price: $116.74 info
Change: -$2.26 (-2%) info
Market Cap: $24.515B info